JO 1784

Known as: JO-1784 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1991-2003
02419912003

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1997
1997
The effects of the chronic administration of the sigma ligand JO 1784 (igmesine) CRF-induced changes in some behavioural, immune… (More)
Is this relevant?
1996
1996
The immobility time in the mouse forced swimming test was dose-dependently reduced by sigma 1 receptor agonists, such as 1-(3,4… (More)
Is this relevant?
1996
1996
Middle cerebral artery occlusion (MCAO) is a widely used surgical procedure for inducing focal cortical ischaemia in mice. In the… (More)
Is this relevant?
1996
1996
We have previously shown in vivo that low doses of selective sigma (sigma) receptor ligands potentiate selectively and dose… (More)
Is this relevant?
1995
1995
To assess the effects of the novel sigma receptor ligand JO 1784 ((+)-N-cyclopropyl-methyl-N-methyl-1,4-diphenyl-1-yl-but-3-en-1… (More)
Is this relevant?
1995
1995
The distribution patterns of M1 and M2 muscarinic receptor subtypes following TMT and JO 1784 administration in the male Sprague… (More)
Is this relevant?
1993
1993
BACKGROUND The ulceroprotective effects of JO 1784 [(+)-N-cyclopropyl-methyl-N-methyl-1,4-diphenyl-1-ethyl-but-3-en-1-yl amine… (More)
Is this relevant?
1992
1992
The central interaction between the sigma receptor ligand, JO 1784, and corticotropin-releasing factor (CRF)-induced inhibition… (More)
Is this relevant?
1992
1992
1. The central interactions between the sigma ligand, JO 1784, [(+)-N-cyclopropylmethyl-N-methyl-1,4-diphenyl-1-ethylbut-3- en-1… (More)
Is this relevant?
1991
1991
JO 1784 ((+)-N-Cyclopropyl-methyl-N-methyl-1,4-diphenyl-1-yl-but-3-en-1-ylami ne, hydrochloride), has been recently described as… (More)
Is this relevant?